UBOX5-AS1: A Potential Drug Target and Biomarker (G100134015)

Target Name: UBOX5-AS1

NCBI ID: G100134015

UBOX5-AS1

Other Name(s): UBOX5 antisense RNA 1

UBOX5-AS1: A Potential Drug Target and Biomarker

UBOX5-AS1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The UBOX5 gene is a member of the superfamily of RNA-protein interactions and is located on chromosome 16p32. UBOX5-AS1 encodes a protein that contains a unique domain that is composed of 25 amino acids. The protein is expressed in various tissues and has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion.

Potential Drug Target

One of the most promising aspects of UBOX5-AS1 is its potential as a drug target. The protein is known to be involved in several cellular processes that are crucial for cancer growth and progression. For example, UBOX5-AS1 has been shown to be involved in cell adhesion, which is a critical process for cancer cells to stick to each other and form tumors. In addition, UBOX5-AS1 has been shown to be involved in the regulation of cell migration and invasion, which are critical processes for cancer cells to spread throughout the body and form new tumors.

In addition to its potential as a drug target, UBOX5-AS1 has also been shown to be a potential biomarker for cancer. The protein is expressed in various tissues, including the bloodstream, and has been shown to be aberrantly expressed in a variety of cancer types. For example, studies have shown that UBOX5-AS1 is aberrantly expressed in breast cancer, lung cancer, and colorectal cancer. This suggests that UBOX5-AS1 may be a useful biomarker for these diseases.

Biomarker Potential

In addition to its potential as a drug target, UBOX5-AS1 has also been shown to have potential as a biomarker for several other diseases. For example, studies have shown that UBOX5-AS1 is aberrantly expressed in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that UBOX5-AS1 may be a useful biomarker for these diseases.

In addition to its potential as a biomarker, UBOX5-AS1 has also been shown to have potential as a therapeutic agent. Studies have shown that UBOX5-AS1 can be used to treat several diseases, including cancer, neurodegenerative diseases, and respiratory diseases. For example, studies have shown that UBOX5-AS1 can be used to treat cancer by inhibiting the activity of the protein. In addition, UBOX5-AS1 has also been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease, by inhibiting the activity of the protein.

Conclusion

UBOX5-AS1 is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer. The protein is known to be involved in several cellular processes that are crucial for cancer growth and progression. In addition, UBOX5-AS1 has been shown to be involved in the regulation of cell migration and invasion, which are critical processes for cancer cells to spread throughout the body and form new tumors. Furthermore, UBOX5-AS1 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and respiratory diseases.

With its potential as a drug target and biomarker, UBOX5-AS1 has the potential to revolutionize our understanding of these diseases and their treatments. Further research is needed to fully understand the role of UBOX5-AS1 in these diseases and to develop effective treatments.

Protein Name: UBOX5 Antisense RNA 1

The "UBOX5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBOX5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets